Calico / AbbVie collaboration announcement demonstrates growth of the Rejuvenation Biotechnology industryPosted by Mike Kope, CEO on September 04, 2014 | Outreach
Reuter's announced today the launch of a Calico/Abbvie agreement. SENS Research Foundation congratulates U.S. drugmaker AbbVie Inc and Calico on the excellent news of their collaboration.
SENS Research Foundation is pleased to announce that its Board has authorized a bridge loan to Arigos Biomedical, Inc.
Mike Kope's message welcoming visitors to our newly-revised site, relaunched in early 2013. It all centers around a new tagline: reimagine aging. Of course we are still "advancing rejuvenation biotechnologies" just as vigorously as when we carried that tagline over the last couple years.
It's with great pleasure that I announce the release of our Annual Report for 2011. The report includes updates on all of our research projects, both at the Research Center in Mountain View, and at leading universities and institutions around the world. It reviews the success of SENS 5 and the expansion of our Academic Initiative, and summarises our financial situation through 2011.
An archived copy of SENS Research Foundation's 2011 Holiday Appeal newsletter.
On 19 September, 2011, Sarah Marr will be stepping down as our Executive Vice President at SENS Foundation. She has been a committed co-founder, and she will of course continue to be a trusted advisor and closely involved with the organization. But we couldn't have her term of full-time service with us pass without noting the significant contribution she has made to the professionalism of the organization and to the quality of our overall message.
Last night, Peter Thiel hosted "Breakthrough Philanthropy", a dinner and presentation event showcasing eight non-profit organizations focused upon game-changing approaches to their fields. It was a wonderful opportunity for us to convey our message to a large group of entrepreneurs and philanthropists interested in the genuinely transformative. Our thanks to the Thiel Foundation, and the Seasteading Institute, for their efforts in creating that event.
On behalf of SENS Foundation, I'm pleased to announce the launch of a competitive research prize for "Breaking Advanced Glycation Endproduct Glucosepane, a Protein Cross-link" through Innocentive, a global leader in open innovation. This $20,000 Theoretical Research prize is designed to give us a clear enough roadmap towards the breakage of glucosepane that we can attract the further financial and scientific resources needed for a full-scale research and development project.